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 CURRENTOPINION Recent advances in primary cutaneous T-cell
lymphoma
Jennifer A. DeSimonea, Pooja Sodhaa, Desislava Ignatovab,
Reinhard Dummerb, Antonio Cozziob, and Emmanuella Guenovab
Purpose of review
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of skin-homing T-cell neoplasms, which
represent approximately 75% of all primary cutaneous lymphomas. Currently available drug therapies,
when effective, simply control disease and the only option for curing CTCL is stem cell transplant.
Recent findings
In the last year, there has been an incredible effort made to improve the understanding and treatment of
CTCL. Recent findings indicate that epigenetic aberrations are integral to active disease. Furthermore,
multiple tumor-derived immunological factors have also been shown to inhibit viability, proliferation, and
cytokine production of nonmalignant T cells. Several novel targeted therapies show great potential, most
promising being antibody drug conjugates targeting surface markers such as CD30 in some CTCL
subtypes. Additional attractive targets involve the global modulation of epigenetic markers such as
demethylation agents or HDAC inhibitors, either as single agents or in combination therapies.
Summary
This is a concise review of recent advances in the field of CTCL with special focus on research articles over
the preceding year.
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INTRODUCTION
Cutaneous T-cell lymphoma (CTCL) is a hetero-
geneous group of skin-homing T-cell neoplasms,
which represent approximately 75% of all primary
cutaneous lymphomas. Mycosis fungoides and
Se´zary syndrome comprise roughly 53% of all CTCL
[1
&&
]. The second most common CTCL type after
mycosis fungoides, cutaneous CD30þ lymphopro-
liferative disorders, comprises 30% of CTCLs, and
includes cutaneous anaplastic large cell lymphoma
and lymphomatoid papulosis [2,3]. Roughly 3% of
CTCLs are comprised of other rare subtypes: subcu-
taneous panniculitis-like T-cell lymphoma (SPTCL)
includes those with the a/b T-cell phenotype [4],
whereas lesions with gamma-delta (gd) T-cell phe-
notype are subcategorized as primary cutaneous gd
T-cell lymphoma [5]. Primary cutaneous CD4þ
small/medium-sized pleomorphic T-cell lymphoma
[6], extranodal NK/T-cell lymphoma [7], aggressive
epidermotropic cutaneous CD8þ lymphoma [8],
angioimmunoblastic T-cell lymphoma [9], hydroa
vacciniforme-like cutaneous T-cell lymphoma [10],
and peripheral T-cell lymphoma, not otherwise
specified (PTCL-NOS) are other rarer subtypes of
CTCL [11]. The clinical picture and prognosis in
CTCL varies widely based on disease subtype and
stage (adapted from the WHO-EORTC classification
of CTCL based on clinical course) [12].
(1) Indolent primary cutaneous T-cell lymphomas
(a) Mycosis fungoides
(b) Mycosis fungoides variants
(i) Folliculotropic mycosis fungoides
(ii) Pagetoid reticulosis
(iii) Granulomatous slack skin
(c) Primary cutaneous CD30þ lymphoprolifer-
ative disorders
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(i) Primary cutaneous anaplastic large cell
lymphoma
(ii) Lymphomatoid papulosis
(d) Subcutaneous panniculitis-like T-cell lym-
phoma
(e) Peripheral T-cell lymphoma (not otherwise
specified)
(i) PrimarycutaneousCD4þ small/medium-
sized pleomorphic T-cell lymphoma
(2) Aggressive primary cutaneous T-cell lympho-
mas
(a) Extranodal NK/T-cell lymphoma, nasal type
(b) Peripheral T-cell lymphoma (not otherwise
specified)
(i) Aggressive epidermotropic cutaneous
CD8þ lymphoma
(ii) Primary cutaneous gamma/delta T-cell
lymphoma
(iii) Primary cutaneous angioimmunoblas-
tic T-cell lymphoma
(iv) Hydroa vacciniforme-like cutaneous
T-cell lymphoma
The most common variant, mycosis fungoides,
generally behaves as a low-grade lymphoma with an
indolent disease course. Most mycosis fungoides
patients (70%) have early-stage disease (stage
IA–IIA) at the time of the initial diagnosis however,
a small subset progress and develop tumors and
extracutaneous dissemination of malignant T cells
[13]. Treatment selection is based on the body
compartment(s) involved. Skin-directed therapies
include topical drugs, phototherapy, and radiation
and are appropriate for limited cutaneous involve-
ment. Systemic agents are utilized in treating blood
and lymphatic disease. Currently available drug
therapies, when effective, simply control disease
and the only option for curing CTCL is stem cell
transplant.
BIOLOGY OF CUTANEOUS T-CELL
LYMPHOMA
The cause of CTCL is not entirely understood; how-
ever, it is recognized that widespread immune dys-
function is a hallmark of advanced disease [14] and
emerging data suggest a role for epigenetic altera-
tions in the pathophysiology of CTCL [15].
RECENT MOLECULAR AND GENOMIC
STUDIES
Amutation clearly linked to clinical disease in CTCL
has yet to be discovered. Recently, a wide array of
gene expression changes has been observed. How-
ever, these aberrant expression patterns are usually
not caused by DNA sequencing mutations, and are
instead the products of aberrant genome transcrip-
tion, implicating epigenetic shifts in the patho-
physiology of CTCL. There is mounting molecular
evidence of epigenetic shifts in CTCL in obser-
vations of gene expression changes, microRNA
(miRNA) dysregulation, altered methylation at gene
promoters, and activity of histone deacetylases.
Somatic mutations in PLCG1 (gene, coding for
phospholipase C, gamma 1) have recently been
identified by Vaque´ et al. [16] in 19% of tissue
samples from 42 mycosis fungoides patients.
Increased downstream signaling toward nuclear fac-
tor of activated T cells activationwas observed in the
PLCG1 mutants and inhibition of this pathway
interrupted CTCL cell proliferation. The authors
proposed that acquisition of PLCG1 mutations
may lead to permissive expansion of CTCL clones
[16].
Intriguing are also the studies by Hashikawa
et al. [17] aimed to identify the mechanism for
epidermotropism in mycosis fungoides and adult
T-cell leukemia/lymphoma (ATLL). Mycosis fun-
goides and ATLL can be clearly differentiated via
complementary cDNA microarray analysis of epi-
dermis and dermis. Downstream upregulation of
skin-homing chemokines and chemokine receptors
has been observed, and increased expression of
lymphotoxin b, CCL21, and CCR10 is found in
mycosis fungoides, whereas CCR4 and CLA expres-
sion is higher for ATLL [17].
miRNAs are small noncoding RNA molecules
that regulate posttranscriptional gene expression.
Several recent miRNA studies document aberrant
expression of miRNAs in CTCL. In Se´zary syndrome
patients, multiple measurable miRNA changes are
observed secondary to alterations in a chromatin
region DNM3 [18]. Upregulation of miR-155,
miR-92a, and miR-93 has been observed in skin
lesions of tumor-stage mycosis fungoides [19].
Mishra and Garzon [20] show that mi-R150 is
KEY POINTS
 No unifying genetic mutation has been identified in
CTCL; however, epigenetic aberrations are integral to
active disease.
 Activation of immune mechanisms supporting Th1
responses is a promising strategy in the treatment
of CTCL.
 Creatively designed trials are needed to examine
multiple variables in this very small population to
examine the utility of specific therapies and the efficacy
of combination regimens, which may afford improved
survival.
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significantly downregulated in advanced CTCL, and
that this downregulation is strongly associated with
tumor invasion/metastasis. McGirt et al. [21] found
reduced levels of miR-223 in blood from late-stage
mycosis fungoides/CTCL and later observed thera-
peutic restoration/increase in miR-223 (as well as
increased miR191 and miR-342) at 3 months post-
extracorporal photophoresis, which was also predic-
tive of a clinical response.
Malignant T lymphocytes in CTCL have been
shown to display widespread promoter hyperme-
thylation associated with inactivation of several
tumor suppressor genes [22]. CD158 (KIR3DL2),
DNM3, PLS3, and TWIST1 are all highly expressed
in mycosis fungoides/Se´zary syndrome and
represent a pattern unique to CTCL [15]. Interest-
ingly, these genes all have large CpG islands and loss
of methylation may be a mechanism for activation
of these genes. Further supporting this notion,
hypomethylation of CpG islands was identified in
CTCL patients [23]. Ferrara et al. [24] evaluated
methylation patterns in 41 mycosis fungoides
patients with Stage 1 disease, looking for patterns
linked to increased risk of progressive disease over
12 years of follow up-observation. Distinct methyl-
ation patterns at four specific loci – LINE-1, PPARG,
SOCS1, and NEUROG1 – were observed in the
patients who progressed to advanced disease and
matched the methylation profile seen in the Se´zary-
derived HUT78 cell line [24]. The role of histone
deacetylases (HDACs) in the pathophysiology of
CTCL has not been widely investigated. One study
examined silent information regulator type-1
(SIRT1), the most known member of the Sirtuin
(Sir2) family of nicotinamide dinucleotide-depend-
ent class III HDACs, and found that SIRT1 is strongly
expressed in both blood and lesional skin in CTCL
[25].
These emerging data provide evidence that epi-
genetic aberrations are integral to active disease in
CTCL and suggest that treatment strategies should
be aimed at regulating multiple epigenetic target
points, possibly through combination regimens.
RECENT IMMUNOLOGICAL STUDIES
CTCL represents malignancies of skin-homing T
cells, and widespread immune dysfunction is a hall-
mark of advanced disease. A recent comprehensive
analysis of the cytokine production of T cells from
leukemic CTCL identifies both malignant and
benign T cells in patients with CTCL to be strongly
Th2-biased. This bias proved to be intrinsic inmalig-
nant cells but extrinsic in benign T cells. Th2 cyto-
kine production by the malignant clone seems to
directly suppress Th1 responses in CTCL patients,
and inhibition of Th2 cytokines leads to recovery of
protective Th1 immune responses [26]. Besides Th2
cytokines, tumor-derived galectins have also been
shown to inhibit viability, proliferation, and Th1
cytokine production of nonmalignant T cells [27]. A
study from Thode et al. [28] further documents
important changes in the epidermis, including
hyperproliferation and loss of the epidermal barrier
function to be driven by tumor-derived galectins in
CTCL. Early CTCL lesions, and especially mycosis
fungoides, often clinically resemble skin lesions of
atopic dermatitis – another Th2-mediated chronic
skin disease [29]. In atopic dermatitis, reduced pro-
duction of antimicrobial peptides in the skin
accounts for frequent infections and impaired
cutaneous immune response. Of interest are two
studies by Suga et al. and Wolk et al. [30,31] that
show lower expression levels of antimicrobial pep-
tides in lesional CTCL skin. Beside tumor-derived
galectins, low level of antimicrobial peptides in
CTCL, as in atopic dermatitis, correlated with barrier
dysfunction and frequent infections of the skin.
Staphylococcus aureus is a common infectious agent,
frequently found in cutaneous CTCL lesions. Krejs-
gaard et al. [32] could demonstrate that staphylo-
coccal enterotoxin can further drive the immune
dysregulation in CTCL patients by inducing a cross-
talk betweenmalignant and benign T cells that leads
to signal transduction and activation of transcrip-
tion (STAT3)-mediated production of immune sup-
pressive interleukin-10 by the malignant T cells.
STAT3 is constitutively phosphorylated and can
further be activated in Se´zary syndrome cells by
interleukin-21 [33]. Thus, both STAT3 and interleu-
kim-21 are potential targets of interest in the treat-
ment of Se´zary syndrome [34].
Recently, two further new cytokines have been
proposed toplay a role in thepathogenesis ofmycosis
fungoides and Se´zary syndrome. A study byOhmatsu
et al. [35] demonstrates elevated interleukin-32
mRNA expression levels in mycosis fungoides and
suggests that interleukin-32 might contribute to the
disease progression. Another study from Singer et al.
[36] reports on elevated serum levels of interleukin-
31 in 14 of 26 pruritic Se´zary syndrome patients. In
three out of three patients with detectablemalignant
T-cell clone, the malignant cells were the predom-
inant producers of interleukin-31 and the clinical
resolutionof pruritus correlatedwithdecreased inter-
leukin-31 levels in the circulation [36].
RECENT THERAPEUTIC ADVANCES IN
CUTANEOUS T-CELL LYMPHOMA
Although there is no unified international algori-
thm for the treatment of CTCL, there are several
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novel therapeutic options to treat CTCL, with
increasing interest in the development of targeted
therapies [37,38].
As mycosis fungoides, the most common form
of CTCL in all age groups, presents frequently with
patch and plaque-stage disease, skin-directed thera-
pies are considered first-line. More recently, the use
of 308-nm excimer laser to treat early-stage (IA–IIA)
diseasewas examined in a small group of six patients
with less than 10% body surface area involvement
refractory to topical therapy. Complete response
was seen in 50% of patients [39
&
]. This modality
may be useful in targeting treatment to anatomi-
cally difficult intertriginous regions while reducing
phototoxicities [39
&
]. Brachytherapy is another well
tolerated and effective therapeutic approach for
difficult regions, such as the delicate facial skin.
We recently conducted a clinical trial aimed to
examine the overall clinical response to low-dose
high-dose-rate brachytherapy in mycosis fungoides.
In 10 patients and 23 facial mycosis fungoides
lesions treated with brachytherapy, a complete
response occurred in six patients (13 lesions) and
a partial response in four patients (10 lesions) [40].
Refractory disease and advanced-staged disease
often require systemic therapy. Systemic therapies
include a number of newly emerging treatments
with increasing effectiveness in stabilizing disease.
THE EUROPEAN ORGANIZATION FOR
RESEARCH AND TREATMENT OF CANCER
Cutaneous Lymphoma Task Force recently pre-
sented the data from two important international
CTCL clinical trials. The European Organization for
Research and Treatment of Cancer (EORTC) trial
21011 was a randomized, open-label phase III trial
evaluating the safety and efficacy of targret in cap-
sules combined with psoralens in combination with
ultraviolet light (PUVA) compared with PUVA alone
in patients with stage IB-IIA CTCL [41]. No signifi-
cant difference in response rate or response duration
was observed; however, a trend toward fewer PUVA
sessions and lower UVA dose required to achieve a
complete clinical response was seen in the combi-
nation arm [41]. EORTC trial 21012 was a phase II
clinical trial with intravenous pegylated liposomal
doxorubicin mono-chemotherapy in patients with
advanced mycosis fungoides (stage IIb, Iva, IVb)
[42]. A total of 49 patients were treated on days 1
and 15 of a 28-day cycle for amedian of 5 cycles. The
overall response rate was 40.8% and median time to
progression and median duration of response were
7.4 and 6 months, respectively [42].
Vorinostat and romidepsin, two histone deace-
tylase inhibitors (HDIs) that are FDA-approved for
the treatment of CTCL, have shown efficacy in
treating relapsing CTCL and in providing extended
response times. Studies to understand the response
mechanisms have shown that HDIs induce cell cycle
arrest and promote apoptosis, though resistance by
suppression of proapoptotic proteins has been
shown in vitro [43]. Overall response rate for both
agents is approximately 33–34% with a durable
response of 12–15 months at best [44,45]. The most
common side-effects are weight loss, weakness,
hematologic abnormalities namely anemia and
thrombocytopenia, nausea/vomiting, and increased
risk of infections [45,46]. Panobinostat is a pan-
deacetylase inhibitor, which was studied in 179
bexarotene-exposed and bexarotene-naı¨ve patients
with CTCL at a dose of 20mg orally three times per
week [47]. The overall response rate was 17.3%.
Reduction in the baseline mSWAT scores were
observed in 74.1% of the patients and the median
duration of response was 5.6 months in the bexar-
otene-exposed patients and was not reached at data
cutoff in the bexarotene-naı¨ve patients. Reported
adverse events include thrombocytopenia, diarrhea,
fatigue, and nausea [47].
Alemtuzumab, an anti-CD52 monoclonal IgG
antibody FDA-approved for the treatment of
relapsed and refractory cutaneous lymphoma, has
shown efficacy in the treatment of advanced myco-
sis fungoides and Se´zary syndrome, though there is
an association with use of this drug and large cell
transformation [48
&
]. Interestingly, overall response
rates in Se´zary syndrome (70%) were higher than
in mycosis fungoides (25%), suggesting that the
systemic treatment is in fact better in targeting
circulating T cells than memory cells residing in
the skin [48
&
,49]. Limiting factors in the use of
alemtuzumab include profound lymphopenia con-
ferring increased risk of systemic infections, ische-
mic colitis, and capillary leak syndrome [48
&
].
Pralatrexate is a novel inhibitor of dihydrofolate
reductase with greater antitumor effect thanmetho-
trexate because of increased internalization by
tumor cells [46]. The overall response rate in one
study assessing dose de-escalation while treating
both advanced mycosis fungoides and Se´zary syn-
drome was 41%, with higher doses noted to have an
overall survival of 51% [46]. In patients that had
progression of disease on methotrexate, a response
rate of 46%was seen, suggesting that another mech-
anism of action may allow pralatrexate to exert its
effect [46]. Common adverse events includedmuco-
sitis, fatigue, nausea, fevers, anorexia, edema, and
anemia, which were balanced with efficacy at a dose
of 15mg/m2 [46].
Data on the effect of brentuximab – an anti-
body–drug conjugate of anti-CD30 monoclonal
Recent advances in primary cutaneous T-cell lymphoma DeSimone et al.
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antibody and the proapoptotic antitubulin agent
monomethylauristatin – in CD30-positive mycosis
fungoides, primary cutaneous ALCL, and other rare
CD30-positive cutaneous entities are currently
being collected [50–52]. A phase III trial in CTCL
is currently recruiting patients. Interim results of a
phase II open-label trial reported an overall response
rate of 44% and mean duration of response of
12 weeks to brentuximab in 27 CD30þ mycosis
fungoides patients (International Investigative
Dermatology Meeting, Edinburgh, Scotland, 2013).
Most recently, progressive multifocal leukoence-
phalopathy (PML) with lethal outcome has been
reported in patients receiving brentuximab for
Hodgkin lymphoma (three patients), primary
cutaneous anaplastic large cell lymphoma (one
patient), and transformedCD30þmycosis fungoides
(onepatient). The threeHodgkin lymphomapatients
and the mycosis fungoides patient developed pro-
gressive neurological deterioration and died soon
after the development of the PML [53
&
].
Chemokine receptor 4 (CCR4) is expressed by T
cells and is important for their recruitment to the
skin [54]. Mogamulizumab is a monoclonal anti-
body against CCR4 that has been developed for
the treatment of diverse hematological malignan-
cies and asthma [55]. Data from a recentmulticenter
phase II trial of mogalizumab in patients with
relapsed peripheral T-cell lymphoma and CTCL
have been published. Objective response was
reported in 13 out of 37 patients (35%) with median
progression-free survival of 3 months [56
&&
]. A phase
III trial is open and actively enrolling patients.
Topical agents that have the ability to activate
the innate immune system have recently been
revisited in the treatment of mycosis fungoides
[57]. Current clinical trials focus mainly on resiqui-
mod – a TLR 7/TLR 8 agonist; cytosine-phosphate-
guanine (CpG) – a TLR9 agonist – has demonstrated
efficacy in CTCL in a phase I clinical trial [58].
CONCLUSION
Recently, there has been an incredible effortmade to
improve the understanding and treatment of CTCL.
Several novel targeted therapies show great promise;
multiple recently discovered proteins seem to be
important in the pathogenesis of CTCL and may
have important implications for the development of
new drugs.
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